Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers
- PMID: 15805280
- DOI: 10.1158/0008-5472.CAN-04-1270
Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers
Abstract
Accelerated cellular senescence (ACS) has been described for tumor cells treated with chemotherapy and radiation. Following exposure to genotoxins, tumor cells undergo terminal growth arrest and adopt morphologic and marker features suggestive of cellular senescence. ACS is elicited by a variety of chemotherapeutic agents in the p53-null, p16-deficient human non-small cell H1299 carcinoma cells. After 10 to 21 days, infrequent ACS cells (1 in 10(6)) can bypass replicative arrest and reenter cell cycle. These cells express senescence markers and resemble the parental cells in their transcription profile. We show that these escaped H1299 cells overexpress the cyclin-dependent kinase Cdc2/Cdk1. The escape from ACS can be disrupted by Cdc2/Cdk1 kinase inhibitors or by knockdown of Cdc2/Cdk1 with small interfering RNA and can be promoted by expression of exogenous Cdc2/Cdk1. We also present evidence that ACS occurs in vivo in human lung cancer following induction chemotherapy. Viable tumors following chemotherapy also overexpress Cdc2/Cdk1. We propose that ACS is a mechanism of in vivo tumor response and that mechanisms aberrantly up-regulate Cdc2/Cdk1 promotes escape from the senescence pathway may be involved in a subset of tumors and likely accounts for tumor recurrence/progression.
Similar articles
-
Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.Anticancer Res. 2000 Mar-Apr;20(2A):693-702. Anticancer Res. 2000. PMID: 10810342
-
p53 regulates Cdc2 independently of inhibitory phosphorylation to reinforce radiation-induced G2 arrest in human cells.Oncogene. 1998 Aug 13;17(6):673-84. doi: 10.1038/sj.onc.1201991. Oncogene. 1998. PMID: 9715268
-
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.Anticancer Res. 1996 Nov-Dec;16(6B):3387-95. Anticancer Res. 1996. PMID: 9042196
-
Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):4-11. Semin Radiat Oncol. 1999. PMID: 10210535 Review.
-
Replicative senescence: mechanisms and implications for human cancer.Pathol Biol (Paris). 2000 Apr;48(3):301-7. Pathol Biol (Paris). 2000. PMID: 10858962 Review.
Cited by
-
Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development.J Cell Mol Med. 2013 Jan;17(1):12-29. doi: 10.1111/jcmm.12001. Epub 2013 Jan 10. J Cell Mol Med. 2013. PMID: 23301705 Free PMC article. Review.
-
Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence.Cell Cycle. 2012 Aug 15;11(16):3132-40. doi: 10.4161/cc.21506. Epub 2012 Aug 8. Cell Cycle. 2012. PMID: 22871735 Free PMC article.
-
Evaluation of the compact high-field orbitrap for top-down proteomics of human cells.J Proteome Res. 2012 Aug 3;11(8):4308-14. doi: 10.1021/pr3004216. Epub 2012 Jul 13. J Proteome Res. 2012. PMID: 22746247 Free PMC article.
-
Therapy-Induced Senescence: Novel Approaches for Markers Identification.Int J Mol Sci. 2024 Aug 2;25(15):8448. doi: 10.3390/ijms25158448. Int J Mol Sci. 2024. PMID: 39126015 Free PMC article. Review.
-
Chromatin-Directed Proteomics Identifies ZNF84 as a p53-Independent Regulator of p21 in Genotoxic Stress Response.Cancers (Basel). 2021 Apr 27;13(9):2115. doi: 10.3390/cancers13092115. Cancers (Basel). 2021. PMID: 33925586 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous